Rare Disease Partnerships Eton's focus on rare diseases and the Galzin launch through Optime Care demonstrate a clear pathway to broaden distribution via specialty pharmacy networks and patient access programs; pursue additional payer and provider partnerships to accelerate adoption.

Collaboration Opportunities The MOU with Key Proteo and ongoing OptimeCare collaboration indicate openness to co-development, licensing, and distribution deals, offering multiple avenues to expand portfolio reach and revenue through external partnerships.

Access and Payer Strategy Rollout of Galzin through a national specialty pharmacy partner highlights payer engagement and formulary positioning as critical levers; advise building robust access programs and payer negotiations to secure broader reimbursement and faster market uptake.

Growth Readiness Leadership changes, including a new CFO appointment and ongoing transition, suggest Eton is positioning for scale and stronger governance; align discussions around long-term supply agreements, manufacturing capacity planning, and strategic financing to support growth initiatives.

Market Reach Ambition Active conference participation and an Illinois-based mid-size footprint signal intent to expand nationally through hospitals, clinics, and specialty distributors; tailor outreach to regional health systems, distribution partners, and patient-advocate channels to build deal flow.